Scleroderma (Systemic Sclerosis) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are high in SSc patients. The only disease-modifying therapies (DMTs) approved for SSc are Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra / RoActemra (tocilizumab), both of which target the SSc-ILD subpopulation and have demonstrated the ability to slow the progressive loss of lung function. Other therapies, such as bosentan (Actelion’s Tracleer, generics) and Bayer’s Adempas (riociguat), are commonly prescribed for overlapping symptoms of PAH. The SSc pipeline is large and diverse, but most agents are in earlier phases of development. Although tremendous need exists for additional effective DMTs, drug development in SSc has been historically challenging owing to the heterogeneity of SSc patients and the commensurate challenges with trial design.
Questions answered
- How large is the diagnosed SSc population in the United States and EU5, and how will it change over the next 10 years?
- What is the current treatment landscape in SSc?
- What is the impact of recently approved therapies, and how will they change the treatment landscape over the next 10 years?
- What do key opinion leaders view as the greatest unmet medical needs in the management of SSc?
- What is the commercial potential of key emerging therapies? How will they fit into the SSc treatment landscape?
Content highlights
- Geographies: United States and EU5
- Primary research: Six country-specific interviews with thought-leading SSc specialists supported by survey data collected for this study.
- Epidemiology: Diagnosed prevalence of SSc cases by country, disease severity, and drug-treatment rates.
- Forecast: Drug-level sales and patient share of key SSc therapies through 2031.
- Emerging therapies: Phase III / PR: 0 drugs; Phase I / II: 11 drugs; coverage of select early-phase products
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Niche & Rare Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
